Product Pathways
Products
GDC0449(Vismodegib)
Structure Price and Availability of GDC0449(Vismodegib)
Size Price Stock
  Contact Us for GDC0449(Vismodegib)
  • Data sheet
  • Details
  • Quality controls
  • Related Products
No.BCP0002 
Product Name:GDC0449(Vismodegib) 
Synonyms:GDC-0449 
Cas No.:879085-55-9 
Apperarnce:white solid 

M.Wt: 421.3

Formula:C19H14Cl2N2O3S

Solubility: DMSO

Purity: >99%

Storage: -20℃ 2 years

 

20G in stock

Our price is one-third of competitors (1g-10g)

 

GDC-0449 is a more potent and specific synthetic oral SMO(signaling transducer Smoothened)inhibitor,with 0.003µM of Gli-luc(Gli-luciferase assay)IC50,GDC-0449,which inhibits the growth of primary pancreatic xenografts without non-specifically inhibiting pancreatic cell proliferation in vitro and has recently entered the clinic.

1. Tremblay MR, Nesler M, Weatherhead R, Castro AC.Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy. Expert Opin Ther Pat. 2009 Jun 8

2. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009 Jun;30(6):303-12. Epub 2009 May 13.

3. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp.Neoplasia. 2009 Jan;11(1):96-101.

4. Molckovsky A, Siu LL.First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting.J Hematol Oncol. 2008 Oct 29;1:20.

5. LoRusso, P.M. et al. (2008) A first-in-human, first-in-class, phase 1 study of systemic Hedgehog pathway antagonist, GDC-0449, in patients with advanced solid tumors. J. Clin. Oncol. 26 (Suppl.), 3516

6. Rudin, C.M. et al. (2008) Updated safety and efficacy data from a firstin-human, first-in-class phase I study of Hedgehog pathway antagonist GDC-0449. European Journal of Cancer Supplements 6, 112?C113

7. Von Hoff, D.D. et al. (2008) Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients [abstract]. 99th AACR Annual Meeting, LB-138

Keywords:buy GDC0449(Vismodegib)|GDC0449(Vismodegib) supplier|purchase GDC0449(Vismodegib)|GDC0449(Vismodegib) cost|GDC0449(Vismodegib) manufactuer|order GDC0449(Vismodegib)|GDC0449(Vismodegib) distributor
 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.